Enhancing mesothelin CAR T cell therapy for pancreatic cancer with an oncolytic herpes virus boosting CAR target antigen expression
Cancer Immunology, Immunotherapy · 14.05.2025 · 74 (7)
DOI: 10.1007/s00262-025-04039-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 14.05.2025. Verfasst von Mona Alhussein Aboalela und 9 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Immune Therapy Research Center, Graduate School of Medicine, Nagoya University, Nagoya, 466-8550, Japan. Hauptthemen laut MEDLINE: Mesothelin, Pancreatic Neoplasms, Oncolytic Virotherapy, Immunotherapy, Adoptive. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Grant-in-Aid for Scientific Research (B), The Japan Grant-in-Aid for Scientific Research (C), Nagoya University.
Abstract (Originalsprache)
Mesothelin (MSLN) is a prominent target antigen for CAR T cell therapy due to its extensive expression in various solid tumors, including pancreatic cancer. However, the therapeutic efficacy of MSLN-targeted CAR T cell therapy has been limited in clinical trials for pancreatic cancer, often resulting in temporary stable disease as the best response. The heterogeneous expression of MSLN and its loss over time, along with the immunosuppressive tumor microenvironment (TME), are key factors restricting effectiveness. Oncolytic viruses are emerging cancer therapies that replicate in tumor cells and remodel the TME into an immunogenic state. Here, we engineered an oncolytic herpes simplex virus type 1 expressing human MSLN (HSV-MSLN) and evaluated its combination with MSLN-CAR T cells in a murine pancreatic ductal adenocarcinoma model. In vitro, HSV-MSLN effectively induced MSLN expression on murine pancreatic cancer cells, with subsequent cell lysis. In co-culture, HSV-MSLN-infected cancer cells activated MSLN-CAR T cells, which effectively eliminated the infected cells. In vivo, HSV-MSLN delivered MSLN on the tumor cell surface and reprogrammed the TME toward an immunogenic state. The combination therapy significantly enhanced antitumor efficacy, inducing activated, proliferative CD8 + CAR T cells and reducing PD-1 + TIM-3 + exhausted endogenous CD8 + T cells and regulatory T cells in tumors. Furthermore, the combination therapy increased migratory XCR1 + CD103 + dendritic cells (DCs) in tumors and tumor-draining lymph nodes (TDLNs) while expanding CD44 + CD8 + T cells with central and effector memory phenotypes. Taken together, these results demonstrate that HSV-MSLN reprograms immune cells in the TME and TDLNs and synergizes with MSLN-CAR T cells to enhance antitumor responses, leading to a more robust therapeutic effect. Graphical abstract MSLN-CAR T cell therapy showed limited efficacy against pancreatic cancer due to heterogeneous antigen expression and an immunosuppressive TME. Here, we engineer the oncolytic virus HSV-MSLN to deliver MSLN and reshape the TME, combining it with MSLN-CAR T cells. Combination therapy reduces tumor burden, enhances CAR T cell activation and proliferation, and decreases exhaustion. Additionally, it increases CD4 + and CD8 + T cell infiltration, enhances CD8 + T cell activation, reduces exhaustion, and decreases Tregs in the tumor. It also elevates migratory DCs in tumors and TDLNs and expands central and effector memory CD8⁺ T cells, promoting a dynamic immune cycle that amplifies antitumor immunity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Immune Therapy Research Center, Graduate School of Medicine, Nagoya University, Nagoya, 466-8550, Japan.
- Department of Gastroenterological Surgery, Graduate School of Medicine, Nagoya University, Nagoya, 466-8550, Japan.
- Department of Medical Microbiology and Immunology, Faculty of Medicine, Zagazig University, Zagazig, 44519, Egypt.
- Department of Microbiology, Faculty of Veterinary Medicine, Zagazig University, Zagazig, 44519, Egypt.
- Cancer Immune Therapy Research Center, Graduate School of Medicine, Nagoya University, Nagoya, 466-8550, Japan. matsumura.shigeru.n9@f.mail.nagoya-u.ac.jp.
- Surgical Oncology Division, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
Förderung
- Japan Grant-in-Aid for Scientific Research (B)
- The Japan Grant-in-Aid for Scientific Research (C)
- Nagoya University
Zitieren
APA
Aboalela, M. A., Abdelmoneim, M., Matsumura, S., Eissa, I. R., Bustos-Villalobos, I., Sibal, P. A., Orikono, Y., Takido, Y., Naoe, Y., & Kasuya, H. (2025). Enhancing mesothelin CAR T cell therapy for pancreatic cancer with an oncolytic herpes virus boosting CAR target antigen expression. Cancer Immunology, Immunotherapy, 74(7). https://doi.org/10.1007/s00262-025-04039-7
Vancouver
Aboalela MA, Abdelmoneim M, Matsumura S, Eissa IR, Bustos-Villalobos I, Sibal PA, et al. Enhancing mesothelin CAR T cell therapy for pancreatic cancer with an oncolytic herpes virus boosting CAR target antigen expression. Cancer Immunology, Immunotherapy. 2025;74(7). doi:10.1007/s00262-025-04039-7
BibTeX
@article{Aboalela2025,
author = {Aboalela, Mona Alhussein and Abdelmoneim, Mohamed and Matsumura, Shigeru and Eissa, Ibrahim Ragab and Bustos-Villalobos, Itzel and Sibal, Patricia Angela and Orikono, Yu and Takido, Yuhei and Naoe, Yoshinori and Kasuya, Hideki},
title = {Enhancing mesothelin CAR T cell therapy for pancreatic cancer with an oncolytic herpes virus boosting CAR target antigen expression},
journal = {Cancer Immunology, Immunotherapy},
year = {2025},
volume = {74},
number = {7},
doi = {10.1007/s00262-025-04039-7}
}
EUVIMED